Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings Report - Pfizer Inc. is set to release its third-quarter earnings results on November 4, with analysts expecting earnings of 64 cents per share, a decrease from $1.06 per share in the same period last year [1] - The consensus estimate for Pfizer's quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier [1] Legal Action - Pfizer has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk in a Delaware Court, claiming breach of contract, breach of fiduciary duty, and tortious interference due to Metsera's failure to meet obligations under a merger agreement with Pfizer [2] - Following the lawsuit, Pfizer's shares rose by 0.04% to close at $24.66 [2] Analyst Ratings - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and reduced the price target from $33 to $32 [5] - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $28 to $30 [5] - Citigroup analyst Andrew Baum maintained a Neutral rating and increased the price target from $25 to $26 [5] - UBS analyst Trung Huynh maintained a Neutral rating and raised the price target from $24 to $25 [5] - Cantor Fitzgerald analyst Carter Gould initiated coverage with a Neutral rating and a price target of $24 [5]